Testofen
Phase 3Small molecule
Testofen is one of 51 small molecule programs targeting Erectile Dysfunction. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
53 competitors in Erectile Dysfunction
#DrugCompanyPhaseTrials
1Cialis
Eli LillyApproved
Levitra
BayerApproved
Viagra
VViatris Specialty LLC
Approved
Rifadin
SanofiApproved
Cipro
BayerApproved
Flomax
SanofiApproved
Avandia
Jazz PharmaceuticalsApproved
Norvir
AbbVieApproved
Avelox
BayerApproved
Caverject
VViatris Specialty LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Testofen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRDC Clinical Pty Ltd